# Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

> **NCT00023699** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group**

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00023699
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023699, "Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00023699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*